Influenza Nucleoprotein Delivered with Aluminium Salts Protects Mice from an Influenza A Virus That Expresses an Altered Nucleoprotein Sequence

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  MacLeod, Megan K L ^a,d   David, Alexandria ^a   Jin, Niyun ^a   Noges, Laura ^a   Wang, Jieru ^b   Kappler, John W ^a,c   Marrack, Philippa ^a,c  

^a HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^b DEPARTMENT OF MEDICINE   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; ALUMINUM SALT; DRUG CARRIER; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2C ANTIBODY; PHOSPHORYL LIPID A; RECOMBINANT INFLUENZA A NUCLEOPROTEIN; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS PROTECTION; DRUG DOSAGE FORM COMPARISON; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; INFLUENZA A; INFLUENZA VACCINATION; LYMPHOCYTE COUNT; MOUSE; NONHUMAN; VIRUS STRAIN;

ANIMALS; B-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; INFLUENZA A VIRUS; INFLUENZA VACCINES; MICE; MICE, INBRED C57BL; NUCLEOPROTEINS; T-LYMPHOCYTES;

ANIMALIA; INFLUENZA A VIRUS; MUS; ORTHOMYXOVIRIDAE;

EID: 84876178716     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0061775     Document Type: Article

References (46)

1. Medina RA, Garcia-Sastre A, (2011) Influenza A viruses: new research developments. Nat Rev Microbiol 9: 590-603.
2. Brown LE, Kelso A, (2009) Prospects for an influenza vaccine that induces cross-protective cytotoxic T lymphocytes. Immunol Cell Biol 87: 300-308.
3. Poland GA, Jacobson RM, Targonski PV, (2007) Avian and pandemic influenza: an overview. Vaccine 25: 3057-3061.
4. Corti D, Voss J, Gamblin SJ, Codoni G, Macagno A, et al. (2011) A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 333: 850-856.
5. Schotsaert M, De Filette M, Fiers W, Saelens X, (2009) Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments. Expert Rev Vaccines 8: 499-508.
6. Wei CJ, Boyington JC, McTamney PM, Kong WP, Pearce MB, et al. (2010) Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science 329: 1060-1064.
7. Heiny AT, Miotto O, Srinivasan KN, Khan AM, Zhang GL, et al. (2007) Evolutionarily conserved protein sequences of influenza a viruses, avian and human, as vaccine targets. PLoS One 2: e1190.
8. Portela A, Digard P, (2002) The influenza virus nucleoprotein: a multifunctional RNA-binding protein pivotal to virus replication. J Gen Virol 83: 723-734.
9. Shu LL, Bean WJ, Webster RG, (1993) Analysis of the evolution and variation of the human influenza A virus nucleoprotein gene from 1933 to 1990. J Virol 67: 2723-2729.
10. Wang M, Lamberth K, Harndahl M, Roder G, Stryhn A, et al. (2007) CTL epitopes for influenza A including the H5N1 bird flu; genome-, pathogen-, and HLA-wide screening. Vaccine 25: 2823-2831.
11. McElhaney JE, Xie D, Hager WD, Barry MB, Wang Y, et al. (2006) T cell responses are better correlates of vaccine protection in the elderly. J Immunol 176: 6333-6339.
12. McMichael AJ, Gotch FM, Noble GR, Beare PA, (1983) Cytotoxic T-cell immunity to influenza. N Engl J Med 309: 13-17.
13. Wilkinson TM, Li CK, Chui CS, Huang AK, Perkins M, et al. (2012) Preexisting influenza-specific CD4(+) T cells correlate with disease protection against influenza challenge in humans. Nat Med 18: 274-280.
14. Endo A, Itamura S, Iinuma H, Funahashi S, Shida H, et al. (1991) Homotypic and heterotypic protection against influenza virus infection in mice by recombinant vaccinia virus expressing the haemagglutinin or nucleoprotein of influenza virus. J Gen Virol 72 (Pt 3): 699-703.
15. Guo L, Zheng M, Ding Y, Li D, Yang Z, et al. (2010) Protection against multiple influenza A virus subtypes by intranasal administration of recombinant nucleoprotein. Arch Virol 155: 1765-1775.
16. MacLeod MK, McKee AS, David A, Wang J, Mason R, et al. (2011) Vaccine adjuvants aluminum and monophosphoryl lipid A provide distinct signals to generate protective cytotoxic memory CD8 T cells. Proc Natl Acad Sci U S A 108: 7914-7919.
17. Price GE, Soboleski MR, Lo CY, Misplon JA, Quirion MR, et al. (2010) Single-dose mucosal immunization with a candidate universal influenza vaccine provides rapid protection from virulent H5N1, H3N2 and H1N1 viruses. PLoS One 5: e13162.
18. Thueng-in K, Maneewatch S, Srimanote P, Songserm T, Tapchaisri P, et al. (2010) Heterosubtypic immunity to influenza mediated by liposome adjuvanted H5N1 recombinant protein vaccines. Vaccine 28: 6765-6777.
19. Ulmer JB, Donnelly JJ, Parker SE, Rhodes GH, Felgner PL, et al. (1993) Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259: 1745-1749.
20. Zhou B, Li Y, Halpin R, Hine E, Spiro DJ, et al. (2011) PB2 residue 158 is a pathogenic determinant of pandemic H1N1 and H5 influenza a viruses in mice. J Virol 85: 357-365.
21. Crawford F, Kozono H, White J, Marrack P, Kappler J, (1998) Detection of antigen-specific T cells with multivalent soluble class II MHC covalent peptide complexes. Immunity 8: 675-682.
22. Cox MM, (2012) Recombinant protein vaccines produced in insect cells. Vaccine 30: 1759-1766.
23. McKee AS, MacLeod MK, Kappler JW, Marrack P, (2010) Immune mechanisms of protection: can adjuvants rise to the challenge? BMC Biol 8: 37.
24. Giannini SL, Hanon E, Moris P, Van Mechelen M, Morel S, et al. (2006) Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 24: 5937-5949.
25. Marrack P, McKee AS, Munks MW, (2009) Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol 9: 287-293.
26. LaMere MW, Lam HT, Moquin A, Haynes L, Lund FE, et al. (2011) Contributions of antinucleoprotein IgG to heterosubtypic immunity against influenza virus. J Immunol 186: 4331-4339.
27. Carragher DM, Kaminski DA, Moquin A, Hartson L, Randall TD, (2008) A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus. J Immunol 181: 4168-4176.
28. de Wit E, Spronken MI, Bestebroer TM, Rimmelzwaan GF, Osterhaus AD, et al. (2004) Efficient generation and growth of influenza virus A/PR/8/34 from eight cDNA fragments. Virus Res 103: 155-161.
29. Zehn D, Turner MJ, Lefrancois L, Bevan MJ, (2010) Lack of original antigenic sin in recall CD8(+) T cell responses. J Immunol 184: 6320-6326.
30. Kees U, Krammer PH, (1984) Most influenza A virus-specific memory cytotoxic T lymphocytes react with antigenic epitopes associated with internal virus determinants. J Exp Med 159: 365-377.
31. Yewdell JW, Bennink JR, Smith GL, Moss B, (1985) Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes. Proc Natl Acad Sci U S A 82: 1785-1789.
32. Hohn H, Neukirch C, Freitag K, Necker A, Hitzler W, et al. (2002) Longitudinal analysis of the T-cell receptor (TCR)-VA and-VB repertoire in CD8+ T cells from individuals immunized with recombinant hepatitis B surface antigen. Clin Exp Immunol 129: 309-317.
33. Rahman F, Dahmen A, Herzog-Hauff S, Bocher WO, Galle PR, et al. (2000) Cellular and humoral immune responses induced by intradermal or intramuscular vaccination with the major hepatitis B surface antigen. Hepatology 31: 521-527.
34. Sebastian R, Skowronski DM, Chong M, Dhaliwal J, Brownstein JS, (2008) Age-related trends in the timeliness and prediction of medical visits, hospitalizations and deaths due to pneumonia and influenza, British Columbia, Canada, 1998-2004. Vaccine 26: 1397-1403.
35. Ambrose CS, Yi T, Walker RE, Connor EM, (2008) Duration of protection provided by live attenuated influenza vaccine in children. Pediatr Infect Dis J 27: 744-748.
36. Hikono H, Kohlmeier JE, Ely KH, Scott I, Roberts AD, et al. (2006) T-cell memory and recall responses to respiratory virus infections. Immunol Rev 211: 119-132.
37. Lamere MW, Moquin A, Lee FE, Misra RS, Blair PJ, et al. (2011) Regulation of antinucleoprotein IgG by systemic vaccination and its effect on influenza virus clearance. J Virol 85: 5027-5035.
38. Lambe T, Spencer AJ, Mullarkey CE, Antrobus RD, Yu LM, et al. (2012) T-cell responses in children to internal influenza antigens, 1 year after immunization with pandemic H1N1 influenza vaccine, and response to revaccination with seasonal trivalent-inactivated influenza vaccine. Pediatr Infect Dis J 31: e86-91.
39. Richards KA, Chaves FA, Alam S, Sant AJ (2012) Trivalent inactivated influenza vaccines induce broad immunological reactivity to both internal virion components and influenza surface proteins. Vaccine.
40. Tetsutani K, Ishii KJ (2012) Adjuvants in influenza vaccines. Vaccine.
41. Garcon N, Vaughn DW, Didierlaurent AM, (2012) Development and evaluation of AS03, an Adjuvant System containing alpha-tocopherol and squalene in an oil-in-water emulsion. Expert Rev Vaccines 11: 349-366.
42. O'Hagan DT, Ott GS, De Gregorio E, Seubert A, (2012) The mechanism of action of MF59- an innately attractive adjuvant formulation. Vaccine 30: 4341-4348.
43. Christensen JP, Doherty PC, Branum KC, Riberdy JM, (2000) Profound protection against respiratory challenge with a lethal H7N7 influenza A virus by increasing the magnitude of CD8(+) T-cell memory. J Virol 74: 11690-11696.
44. Furuya Y, Chan J, Regner M, Lobigs M, Koskinen A, et al. (2010) Cytotoxic T cells are the predominant players providing cross-protective immunity induced by {gamma}-irradiated influenza A viruses. J Virol 84: 4212-4221.
45. Belz GT, Bedoui S, Kupresanin F, Carbone FR, Heath WR, (2007) Minimal activation of memory CD8+ T cell by tissue-derived dendritic cells favors the stimulation of naive CD8+ T cells. Nat Immunol 8: 1060-1066.
46. Grimm D, Staeheli P, Hufbauer M, Koerner I, Martinez-Sobrido L, et al. (2007) Replication fitness determines high virulence of influenza A virus in mice carrying functional Mx1 resistance gene. Proc Natl Acad Sci U S A 104: 6806-6811.